BioLineRx Ltd. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K, dated November 21, 2024, reports material events for BioLineRx Ltd., a foreign private issuer. The filing details a strategic pivot involving the licensing of its lead product, motixafortide (APHEXDA), and a concurrent capital raise to fund operations and pipeline expansion.
Key Financial Metrics and Transactions
- License Agreement: Entered into an exclusive license with Ayrmid Pharma Ltd. for motixafortide (non-solid tumor indications, non-Asia territories).
- Upfront payment: $10 million (non-refundable).
- Commercial milestones: Up to $87 million based on sales targets.
- Royalties: Tiered double-digit range (18-23%) on net sales.
- Registered Direct Offering: Sale of 16,471,449 ADSs (or pre-funded warrants) plus warrants to purchase 8,235,724 ADSs.
- Expected gross proceeds: $9.0 million.
- Price: $0.5464 per ADS and accompanying warrant.
- Debt Restructuring: Amended loan agreement with BlackRock EMEA Venture and Growth Lending.
- Partial repayment: $16.5 million (cancels future revenue-based payments).
- Remaining balance: Repayable over three years ending December 1, 2027.
- Cash balance requirement: Reduced to $4 million.
- Historical Revenue (Preliminary): Approximately $17.2 million for the nine months ended September 30, 2024 (includes $4.5 million from Aphexda).
- Liquidity: Preliminary unaudited cash, cash equivalents, and short-term deposits expected to be approximately $20 million immediately following the closing of the license and offering.
Material Changes and Operational Shifts
The company is executing a significant reduction in its U.S. commercial footprint to lower cash burn. Key changes include:
- Workforce Reduction: Full shutdown of U.S. commercial operations and transition of certain U.S. commercial staff to Ayrmid Pharma.
- Leadership Change: Ms. Holly May stepping down as President of BioLineRx USA Inc.
- Cash Burn Reduction: Cost-cutting measures are expected to reduce annual cash burn by approximately 70%, effective January 1, 2025.
- Supply Chain: BioLineRx will supply motixafortide to Ayrmid on a cost-plus basis under a new Supply Agreement.
Outlook, Risks, and Contingencies
- Use of Proceeds: Net proceeds from the offering will fund general corporate purposes, the pancreatic program, and pipeline expansion.
- Conditions Precedent: The debt amendment and offering closing are subject to conditions, including receipt of the $10 million upfront license payment.
- Upstream Dependency: The License Agreement with Ayrmid terminates if BioLineRx's upstream license with Biokine Therapeutics Ltd. is terminated.
- Investor Restrictions: Investors in the offering are subject to lock-up restrictions on 20% of shares for 90 days or until the stock price exceeds $0.6557. Standstill and voting restrictions apply for 12 months.
- Financial Advisory: MTS Health Partners served as exclusive financial advisor for a $2 million fee.
Investor Verification Checklist
- Confirm the closing of the Registered Direct Offering and receipt of the $9.0 million gross proceeds.
- Verify receipt of the $10 million upfront payment from Ayrmid Pharma to trigger the debt amendment.
- Monitor the execution of the 70% cash burn reduction and the timeline for the U.S. commercial shutdown.
- Review the status of the upstream license with Biokine Therapeutics Ltd., as its termination would void the Ayrmid agreement.
- Assess the dilution impact of the 16.5 million ADSs and associated warrants issued in the offering.